Browsing by Subject "Escherichia coli infection"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection
    (Maney Publishing, 2010) Senol S.; Tasbakan M.; Pullukcu H.; Sipahi O.R.; Sipahi H.; Yamazhan T.; Arda B.; Ulusoy S.
    The aim of this observational prospective study was to compare the effect of fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in the treatment of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli-related complicated lower urinary tract infection (CLUTI). Inclusion criteria were: patients who were aged >18 yr with dysuria or problems with frequency or urgency in passing urine; those with >20 leukocytes/mm3 in urine microscopy and culture-proven ESBL-producing carbapenem or FT-sensitive E. coli in the urine (>10 5 cfu/mm3); no leukocytosis or fever; and who were treated with FT (oral 3 g sachet x 1 every other night, three times) or carbapenems between March 2005 and January 2006 in our outpatient clinic and hospital. A total of 47 CLUTI attacks in 47 patients (27 FT group, 20 carbapenem group) were observed prospectively. Clinical and microbiological success in the carbapenem and FT groups was similar (19/20 vs 21/27 and 16/20 vs 16/27 p>0.05). Drug acquisition costs were significantly lower in the FT group (p<0.001). Although it is not a randomized controlled study, these data show that FT may be a suitable, effective and cheap alternative in the treatment of ESBL-producing E. coli-related CLUTI. © E.S.I.F.T. srl.
  • No Thumbnail Available
    Item
    Community-acquired pneumonia in patients with chronic obstructive pulmonary disease requiring admission to the intensive care unit: Risk factors for mortality
    (2013) Cilli A.; Erdem H.; Karakurt Z.; Turkan H.; Yazicioglu-Mocin O.; Adiguzel N.; Gungor G.; Bilge U.; Tasci C.; Yilmaz G.; Oncul O.; Dogan-Celik A.; Erdemli O.; Oztoprak N.; Samur A.A.; Tomak Y.; Inan A.; Karaboga B.; Tok D.; Temur S.; Oksuz H.; Senturk O.; Buyukkocak U.; Yilmaz-Karadag F.; Ozcengiz D.; Karakas A.; Savasci U.; Ozgen-Alpaydin A.; Kilic E.; Elaldi N.; Bilgic H.
    Purpose: The aims of this study are to identify factors predicting mortality in patients with chronic obstructive pulmonary disease (COPD) and community-acquired pneumonia (CAP) requiring intensive care unit (ICU) admission and to examine whether noninvasive ventilation treatment reduces mortality. Materials and Methods: An analysis was performed on data from patients with CAP hospitalized in the ICUs of 19 different hospitals in Turkey between October 2008 and January 2011. Predictors of mortality were assessed by both univariate and multivariate statistical analyses. Results: Two hundred eleven patients with COPD and CAP were included. The overall ICU mortality was 23.9%. Noninvasive ventilation treatment (odds ratio [OR], 0.12; 95% confidence interval [CI], 0.03-0.49; P = .003), hypertension (OR, 0.13; 95% CI, 0.02-0.93; P = .042), bilateral infiltration (OR, 13.92; 95% CI, 2.94-65.84; P = .001), systemic corticosteroid treatment (OR, 0.19; 95% CI, 0.35-0.96; P = .045), length of ICU stay (OR, 0.65; 95% CI, 0.47-0.89; P = .007), and duration of invasive mechanical ventilation (OR, 1.11; 95% CI, 1.01-1.22; P = .032) were independent factors related to mortality. Conclusion: Noninvasive ventilation, hypertension, systemic corticosteroid treatment, and shorter ICU stay are associated with reduced mortality, whereas bilateral infiltration and longer duration of invasive mechanical ventilation are associated with increased risk of mortality in patients with COPD and CAP requiring ICU admission. © 2013 Elsevier Inc.
  • No Thumbnail Available
    Item
    Gamma scintigraphy and biodistribution of 99mTc-cefotaxime sodium in preclinical models of bacterial infection and sterile inflammation
    (John Wiley and Sons Ltd, 2016) Ilem-Ozdemir D.; Asikoglu M.; Ozkilic H.; Yilmaz F.; Hosgor-Limoncu M.; Ayhan S.
    99mTc-cefotaxime sodium (99mTc-CEF) was developed and standardized under varying conditions of reducing and antioxidant agent concentration, pH, radioactivity dose, and reducing agent type. Labeling studies were performed by changing the selected parameters one by one, and optimum labeling conditions were determined. After observing the conditions for maximum labeling efficiency and stability, lyophilized freeze dry kits were prepared accordingly. Simple method for radiolabeling of CEF with 99mTc has been developed and standardized. Labeling efficiency of 99mTc-CEF was assessed by both radio thin-layer chromatography and radio high-performance liquid chromatography and found higher than 90%. The labeled compound was found to be stable in saline and human serum up to 24 h. Two different freeze dry kits were developed and evaluated. Based on the data obtained from this study, both products were stable for 6 months with high labeling efficiency. The prepared cold kit was found sterile and pyrogen free. The bacterial infection and sterile inflammation imaging capacity of 99mTc-CEF was evaluated. Based on the in vivo studies, 99mTc-CEF has higher uptake in infected and inflamed thigh muscle than healthy thigh muscle. Cefotaxime sodium (CEF) was successfully labeled with 99mTc from newly developed instant kit. Radiochemical purity was found greater than 90% and the labeled compound was stable in human serum during incubation period up to 24 h. The improved kit was found to be sterile, pyrogen free and stable up to 6 months. According to gamma scintigraphy studies, 99mTc-CEF showed a higher uptake in bacterial infected and sterile inflamed muscle than healthy thigh muscle. © Copyright 2016 John Wiley & Sons, Ltd.